Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab combined with NSOX as neoadjuvant therapy for operable gastric cancer
ChiCTR2300071844Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab, paclitaxel, oxaliplatin and tegafur + gimeracil + oteracil in gastric cancer (GC) and gastric adenocarcinoma, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Major pathological response rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
envafolimabpaclitaxeloxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300071844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071844.